ImmunityBio Inc (IBRX)

ImmunityBio's stock price has experienced significant fluctuations in the past six months. The share price as of March 31, 2026, was $7.65, representing a substantial increase of 158.45% from April 1, 2025. The company's stock has faced downward pressure due to regulatory concerns, including a warning letter from the FDA citing misleading promotional materials for Anktiva, which triggered multiple securities fraud class action lawsuits. However, the stock has also seen positive movements following the conditional EU marketing authorization for Anktiva, positive full-year 2025 financial results, and the NCCN updating its 2026 bladder cancer guidelines to include Anktiva plus BCG for a broader patient population.

Specific seasonal fluctuations in demand for ImmunityBio's products are not explicitly detailed; however, the company has reported strong demand and increased sales momentum for Anktiva. Repeat prescribing has been identified as a major driver of sales growth, and the ongoing shortage of BCG has also contributed to the demand for Anktiva. Demand is likely driven more by disease prevalence, treatment efficacy, regulatory approvals, and market access rather than typical seasonal patterns.

ImmunityBio, Inc. is a biotechnology company focused on developing and commercializing next-generation immunotherapies to combat cancer and infectious diseases, operating within the healthcare sector. Its core business revolves around activating the patient's immune system to provide durable protection against various diseases, utilizing proprietary platforms for developing biologic products and product candidates. The company's flagship product is Anktiva, an FDA-approved immunotherapy used in combination with BCG for the treatment of adult patients with BCG-unresponsive NMIBC. ImmunityBio's pipeline includes therapeutic agents in clinical trials for liquid and solid tumors, and it is also exploring treatments for infectious diseases like HIV.

ImmunityBio has rapidly expanded its global presence, with Anktiva approved or authorized in approximately 34 countries across five regulatory jurisdictions, including the United States, the United Kingdom, the European Union, Saudi Arabia, and Macau SAR, China. The company has established distribution partnerships with Accord Healthcare in the European Union and with BioPharma & Cigalah to expand access in Saudi Arabia and the broader MENA region.

In the past year, ImmunityBio's brand reputation has been significantly impacted by regulatory issues, including a formal warning letter from the FDA regarding misleading promotional materials for Anktiva. The FDA alleged that a TV advertisement and a podcast made unsupported claims, suggesting Anktiva could cure and prevent all types of cancer, which goes beyond its approved indication for bladder cancer. These events led to multiple securities fraud class action lawsuits.

ImmunityBio's ownership structure includes institutional, insider, and retail investors. Dr. Patrick Soon-Shiong, along with affiliated entities, beneficially owns approximately 66.3% of the company's common stock. Major institutional owners include Vanguard Group Inc., BlackRock, Inc., State Street Corp, Jane Street Group, Llc, Geode Capital Management, Llc, and Goldman Sachs Group Inc.